Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 150 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mannitol Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability

NCT02603822
View directory record Official record
Conditions
Impaired Small Intestinal Permeability
Interventions
12C mannitol, Indomethacin, 13C mannitol, Lactulose
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

NCT04401579
View directory record Official record
Conditions
COVID-19
Interventions
Placebo, Remdesivir, Baricitinib
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 18, 2026, 4:51 AM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib

NCT01645085
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MCC-based 13% drug loaded tablets, Mannitol-based 38% drug-loaded tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 18, 2026, 4:51 AM EDT
Terminated Not applicable Interventional Results available

Furosemide vs Placebo for Brain Relaxation

NCT01054404
View directory record Official record
Conditions
Brain Swelling, Brain Edema, Dehydration
Interventions
Furosemide, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

NCT00669331
View directory record Official record
Conditions
Bronchiectasis
Interventions
Inhaled mannitol, Matched control
Drug
Lead sponsor
Syntara
Industry
Eligibility
18 Years to 85 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
19
States / cities
Denver, Colorado • Farmington, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 18, 2026, 4:51 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Results available

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

NCT03000283
View directory record Official record
Conditions
Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Stroke
Interventions
Conivaptan
Drug
Lead sponsor
Jesse Corry
Other
Eligibility
19 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

NCT00968240
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

NCT00514540
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Carboplatin, Etoposide, Cisplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis

NCT05740618
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Mannitol Inhalant Product
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 18, 2026, 4:51 AM EDT
Not yet recruiting Early Phase 1 Interventional

hCG Treatment for Rehabilitation From a TBI

NCT07557615
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Ovidrel, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 2 Interventional

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

NCT00069017
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MEDI-522, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2007 · Synced Oct 18, 2026, 4:51 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

NCT00951743
View directory record Official record
Conditions
HIV Infections
Interventions
Adaptavir (monomeric DAPTA)
Drug
Lead sponsor
Rapid Laboratories Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2009 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Results available

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

NCT01290302
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Interventions
Luitpold Azacitidine, Vidaza®
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prebiotic Effects of Isomalto-oligosaccharide

NCT02433873
View directory record Official record
Conditions
Microbiota
Interventions
Isomalto-oligosaccharide
Dietary Supplement
Lead sponsor
George Mason University
Other
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 18, 2026, 4:51 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Tranexamic Acid in Adherent Placenta (TAP)

NCT02329756
View directory record Official record
Conditions
Placenta Accreta
Interventions
Tranexamic Acid (TXA), Sodium Chloride 0.9%
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA

NCT01180816
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Super-Selective Intraarterial Intracranial Infusion of Temozolomide
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Phase 3 Interventional Results available

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 18, 2026, 4:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects for Midface Improvement When Pairing a Biostimulator with a Skincare Regimen

NCT05963204
View directory record Official record
Conditions
Photodamaged Skin, Volume Deficiency of the Midface
Interventions
Sculptra and Alastin Restorative Skin Complex, Sculptra and CeraVe Daily Moisturizing Lotion
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 18, 2026, 4:51 AM EDT
Recruiting Phase 2 Interventional

Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy

NCT07434492
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Smart Ankle-Foot Orthosis, 5-Azacitidine, Placebo
Device · Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
8 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 18, 2026, 4:51 AM EDT
Recruiting Phase 2 Interventional

Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation

NCT07501078
View directory record Official record
Conditions
Ulcerative Colitis, Ileal Pouch
Interventions
Aquamin, Placebo
Drug
Lead sponsor
Muhammad N Aslam, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 4:51 AM EDT